Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dronabinol MDI · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Dronabinol MDI | DRUG | - |
Inclusion Criteria: * Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria Exclusion Criteria: * Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous in...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
Dronabinol MDI is an investigational metered dose inhaler formulation of dronabinol being developed by Nektar Therapeutics. It is a small molecule therapy in Phase 2 clinical development for the acute treatment of migraine with aura. The inhaler delivers a controlled dose of dronabinol directly to the lungs.
Dronabinol MDI is being studied for the acute treatment of migraine headache in patients with migraine with aura. It is intended to provide rapid relief during a migraine attack. The drug is investigational and has not been approved for any indication.
Dronabinol MDI targets the cannabinoid receptor 1, also known as CNR1. It acts as an agonist at this receptor. CNR1 is a G protein-coupled receptor found primarily in the central nervous system and is involved in modulating pain and other neurological processes.
Dronabinol MDI is being developed by Nektar Therapeutics, which trades on the Nasdaq under the ticker symbol NKTR. Nektar is a biopharmaceutical company focused on developing therapeutics in areas including neurology.
Dronabinol MDI is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 program is focused on evaluating the drug in patients with migraine with aura.
Dronabinol MDI has been evaluated in a completed Phase 2 trial, NCT00123201, titled Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache. The trial enrolled adults aged 18 years and older in the United States and included patients with migraine with aura and migraine without aura.